Knee OA: Growing Demand For Nonsurgical Options

The knee replacement market is posting flat growth across the board as more patients seek nonsurgical options to manage their pain. Although such treatments typically last only a few months, many patients willingly accept the durability tradeoff to avoid the cost and downtime associated with surgery.

Knee osteoarthritis (OA) is striking patients at a much younger age – 16 years earlier than in the 1990s, according to a recent study by researchers from Brigham and Women’s Hospital – a finding that underscores the need for new technologies to address knee pain and possibly reverse this disturbing trend. Currently, 7% of Americans aged 45+ years are diagnosed with knee OA and the mean age of onset was 56 years in 2010 versus 72 years in the 1990s, the researchers told attendees at the 2011 American College of Rheumatology (ACR) Annual Meeting, held last month in Chicago, IL.

Over the next decade, 6.5 million Americans aged 35-84 years are expected to be diagnosed with knee OA and those aged 45-64 will comprise more than half of those cases....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Guardant Health Launches Germline Hereditary Cancer Test

 

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.